Clinical Trial Update: Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating rhAngiostatin in combination with paclitaxel and carboplatin for non-small cell lung cancer has completed, reporting safety and effic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• rhAngiostatin (recombinant human angiostatin)

Snippet

Sponsor: CASI Pharmaceuticals, Inc. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED